Ptc Therapeutics executive Neil Almstead sells shares worth $133,674

Neil Gregory Almstead, the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), recently executed a series of transactions involving the sale of company shares. According to a recent SEC filing, Almstead sold a total of 2,979 shares over two days, with transactions occurring on January 7 and January 8, 2025. The transactions come amid a strong performance period for PTCT, with the stock showing a 56% return over the past year and a notable 42% gain in the last six months, according to InvestingPro data.

On January 7, Almstead sold 1,265 shares at a price of $45.34 each, and an additional 55 shares were sold by his spouse at the same price. The next day, January 8, he sold 1,552 shares at $44.50 per share, and 107 shares were sold by his spouse at the same price. The total value of these transactions amounted to approximately $133,674, with share prices ranging from $44.50 to $45.34. With a current market capitalization of $3.4 billion, InvestingPro analysis indicates the stock is trading above its Fair Value, with analyst price targets ranging from $32 to $80.

These sales were executed under an irrevocable sell-to-cover election, a common practice to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Almstead retains direct ownership of 103,231 shares, while his spouse holds 5,975 shares indirectly. The company maintains strong liquidity with a current ratio of 2.1, and receives a "GOOD" overall financial health rating from InvestingPro.

In other recent news, PTC (NASDAQ:PTC) Therapeutics has experienced significant developments. The biopharmaceutical company has submitted an FDA application for vatiquinone, a potential treatment for Friedreich ataxia. Supported by data from the MOVE-FA study and two long-term studies, the application marks a major milestone for the company. In another development, PTC Therapeutics has amended its lease agreement with Warren CC Acquisitions, reducing its rented space and adjusting financial terms.

Furthermore, the company entered into a lucrative global license and collaboration agreement with Novartis (SIX:NOVN) for the Huntington's disease treatment PTC518, which includes a $1 billion cash payment upfront. As a result, Morgan Stanley (NYSE:MS) upgraded the company's stock from Equalweight to Overweight and set a new price target of $67.00. Meanwhile, TD Cowen analyst outlined ten anticipated catalysts for the year 2025, including several related to PTC Therapeutics.

These are recent developments in the operations of PTC Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.